Azithromycin for mild-to-moderate COVID-19.

Patel, Jigar; Berezowski, Ivan; Abdelmonem, Ahmed; Taylor, Dania; Pourmand, Ali

Patel, Jigar; Berezowski, Ivan; Abdelmonem, Ahmed; Taylor, Dania; Pourmand, Ali.

Patel J; International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA. Electronic address: jigar.r.patel@outlook.com.
Berezowski I; International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Abdelmonem A; International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Taylor D; International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Pourmand A; International Medicine Program, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

Lancet Respir Med ; 9(10): e99, 2021 10.

Article in English | MEDLINE | ID: covidwho-1671357

Subject(s)

Azithromycin; COVID-19 Drug Treatment; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azithromycin / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google